Navigation Links
Researchers seek children for a study of antibiotics for a urinary tract disorder
Date:6/20/2008

logy program in the Division of Kidney, Urologic, and Hematologic Diseases. "In addition to finding out if antibiotics reduce the risk of UTIs, we also need to understand the progression of renal scarring and the development of resistance to antibiotics in these children."

The researchers seek to enroll 600 participants. So far, 125 infants and children have joined the study. Participants must be between the ages of 2 months and 6 years and have had their first UTI within the six weeks before their first study visit. With the approval of 20 institutional review boards and an external data safety monitoring board charged with overseeing the safety of children in the trial, each participant receives a daily dose of an antibiotic or a placebo for up to two years. Children who develop recurring fever or other symptoms of infection or scar tissue buildup in the kidney will be switched from the study to routine antibiotic care and referred to a urologist, depending on the number of infections and degree of renal scarring.


'/>"/>

Contact: Arthur Stone
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Researchers confirm benzene-like electron delocalization of important molecule
2. Penn researchers find key developmental pathway activates lung stem cells
3. MIT researchers see alternative to common colorectal cancer drug
4. $10 million gift will retain and recruit world-class researchers to University at Buffalo
5. Researchers ID Traits of Aggressive Prostate Cancer
6. Carnegie Mellon researchers improve assessments of aortic aneurysms
7. Chemical engineering researchers identify biofilms that cause infections
8. MU researchers enhancing motion-capture technology to benefit older adults
9. Researchers Update Risk-of-Death Charts
10. Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients
11. Rutgers researchers show how the brain can protect against cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 1Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 3Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 4Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 1Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 2
Other Medicine Technology:NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 2NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 3NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 4NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 5NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 6Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 2Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 3Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 4Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 5Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 6